Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

...

187

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
A04AA01	ONDANSETRON HIKMA	G	Ondansetron (HCl dihydrate) - 8mg/4ml	8mg/4ml	Injectable solution	4,018,089 L.L
A04AA01	ONDANSETRON MEDIS	G	Ondansetron - 8mg/4ml	8mg/4ml	Injectable solution	1,919,007 L.L
A04AA01	ONDANSETRON RENAUDIN	G	Ondansetron (HCl dihydrate) - 8mg/4ml	8mg/4ml	Injectable solution	2,433,699 L.L
A04AA01	ONDANSETRON VIANEX	G	Ondansetron (HCl) - 8mg/4ml	8mg/4ml	Injectable solution	387,027 L.L
A04AA01	TRONDAMET	G	Ondansetron (HCl) - 8mg/4ml	8mg/4ml	Injectable solution	2,027,858 L.L
A04AA01	α ONDANSETRON USP	G	Ondansetron - 8mg/4ml	8mg/4ml	Injectable solution	447,948 L.L
A04AA01	NOZAMET	G	Ondansetron - 8mg	8mg	Film, orodispersible	6,075,448 L.L
A04AA01	ONDANSETRON ARROW	G	Ondansetron - 8mg	8mg	Tablet, orodispersible	1,280,682 L.L
A04AA01	ONZETRAN OD	G	Ondansetron - 8mg	8mg	Tablet, orodispersible	1,023,880 L.L
A04AA01	ZONETRON ODT	G	Ondansetron - 8mg	8mg	Tablet, orodispersible	998,283 L.L
A04AA01	NAUSETRON	G	Ondansetron - 4mg/5ml	4mg/5ml	Solution	958,608 L.L
A04AA01	NAUSETRON	G	Ondansetron - 4mg/5ml	4mg/5ml	Solution	802,466 L.L
A04AA01	ONDEMED	G	Ondansetron (HCl) - 4mg/5ml	4mg/5ml	Solution	858,779 L.L
A04AA01	ONZO	G	Ondansetron (HCl dihydrate) - 4mg/5ml	4mg/5ml	Solution	2,687,685 L.L
A04AA01	VOMITRON	G	Ondansetron (HCl) - 4mg/5ml	4mg/5ml	Solution	858,779 L.L
A04AA01	VOMITRON	G	Ondansetron (HCl) - 4mg/5ml	4mg/5ml	Solution	304,604 L.L
A04AA01	NOZAMET	G	Ondansetron - 4mg	4mg	Film, orodispersible	3,234,181 L.L
A04AA01	ZONETRON ODT	G	Ondansetron - 4mg	4mg	Tablet, orodispersible	972,686 L.L
A04AA01	VOMITRON	G	Ondansetron - 16mg	16mg	Suppository	578,492 L.L
A04AA01	VOMITRON	G	Ondansetron - 16mg	16mg	Suppository	304,604 L.L
A04AA02	KYTRIL	B	Granisetron (HCl) - 1mg	1mg	Tablet, film coated	2,765,628 L.L
A04AA02	GRANI-DENK	G	Granisetron - 1mg/ml	1mg/ml	Injectable concentrate for solution	893,655 L.L
A04AA02	KYTRIL	B	Granisetron (HCl) - 3mg/3ml	3mg/3ml	Injectable solution	3,711,693 L.L
A04AA02	GRANI-DENK	G	Granisetron - 3mg/3ml	3mg/3ml	Injectable concentrate for solution	1,679,803 L.L
A04AA02	NEOSET	G	Granisetron (HCl) - 3mg/3ml	3mg/3ml	Injectable solution	405,840 L.L
A04AA02	SANCUSO	G	Granisetron - 3.1mg/24h	3.1mg/24h	Patch	7,590,728 L.L
A04AA05	ALOXI	B	Palonosetron HCl - 0.25mg/5ml	0.25mg/5ml	Injectable solution	3,656,595 L.L
A04AA05	PALONAN	G	Palonosetron HCl - 250mcg/5ml	250mcg/5ml	Injectable solution	2,194,495 L.L
A04AA05	VONAXI	G	Palonosetron HCl - 250mcg/5ml	250mcg/5ml	Injectable solution	1,490,321 L.L
A04AA55	AKYNZEO	B	Palonosetron - 0.5mg, Netupitant - 300mg		Capsule, hard	7,364,372 L.L

...

187